MI-538 manufacturers
- MI-538
-
- $58.00
-
2026-05-11
- CAS:1857417-10-7
- Purity: 99.80%
- Supply Ability: 10g
|
| Product Name: | MI-538 | | Synonyms: | MI-538;MI538; MI 538;1H-Indole-2-carbonitrile, 6-hydroxy-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-;MI538,inhibit,Epigenetic Reader Domain,Inhibitor,MI-538,MI 538;1-((1H-pyrazol-4-yl)methyl)-6-hydroxy-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile;MI-538, 10 mM in DMSO | | CAS: | 1857417-10-7 | | MF: | C27H25F3N8OS | | MW: | 566.6 | | EINECS: | | | Product Categories: | | | Mol File: | 1857417-10-7.mol |  |
| | MI-538 Chemical Properties |
| Boiling point | 812.0±65.0 °C(Predicted) | | density | 1.56±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (176.49 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 9.46±0.40(Predicted) | | color | White to off-white |
| | MI-538 Usage And Synthesis |
| Uses | MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM. | | in vivo | Treatment with MI-538 results in a pronounced, about 80%, reduction in the MV4;11 tumor volume, without causing substantial signs of toxicity reflected by less than 10% reduction of the body weight. MI-538 demonstrates markedly improved exposure (area under the curve, AUC, values), Cmax (maximum compound concentration) in the blood plasma, and the lowest value of clearance. The half-life of MI-538 is about 1.6 h. MI-538 has also high oral bioavailability (~50%)[1]. | | References | [1] Borkin D, et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. DOI:10.1021/acs.jmedchem.5b01305 |
| | MI-538 Preparation Products And Raw materials |
|